ABSTRACT
Background Cerebral visual impairment (CVI) is the commonest form of paediatric visual impairment in developed countries. CVI can arise from a host of genetic or acquired causes, but there has been limited research to date on CVI in the context of genetic disorders.
Methods We carried out a retrospective analysis of genotypic and phenotypic data for participants with CVI within the DECIPHER database and 100,000 Genomes Project (100KGP).
Results 158 individuals with CVI were identified across both cohorts. Within this group, pathogenic or likely pathogenic sequence variants in 173 genes were identified. 25 of these genes already have known associations with CVI, whilst the remaining 148 are candidate genes for this phenotype. Gene Ontology analysis of the CVI gene sets from both DECIPHER and 100KGP suggest that CVI has a similar degree of genetic heterogeneity to other neurodevelopmental phenotypes, and a strong association with genetic variants converging on ion channels and receptor functions. Individuals with a monogenic disorder and CVI have a higher frequency of epilepsies and severe neurodisability than individuals with a monogenic disorder but not CVI.
Conclusion This study supports the availability of genetic testing for individuals with CVI alongside other neurodevelopmental difficulties. It also supports the availability of ophthalmological screening for individuals with genetic diagnoses linked to CVI. Further studies could elaborate on the links between specific genetic disorders, visual maturation and broader neurodevelopmental characteristics.
What is known about the subject?
CVI is the most prevalent form of paediatric-onset visual impairment in the developed world.
CVI commonly occurs alongside other neurodevelopmental phenotypes such as epilepsies, global developmental delay, cerebral palsy, ADHD and autism.
CVI is known to have genetic aetiology, which is often undiagnosed.
What this study adds?
This study reports CVI-associated genetic diagnoses and phenotypic associations for two large cohorts
Gene ontology annotations have been analysed for candidate CVI genes
How this study might affect research, practice or policy
This study has implications for genetic testing in children with CVI
This study has implications for CVI screening in children with a genetic diagnosis
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support. This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from https://deciphergenomics.org/about/stats and via email from contact{at}deciphergenomics.org. DECIPHER is hosted by EMBL-EBI and funding for the DECIPHER project was provided by the Wellcome Trust [grant number WT223718/Z/21/Z].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves data previously collected for human participants, which was approved for Genomics England by Research Ethics Committee, East of England Cambridge South. Participants gave informed consent to participate in the study before taking part.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests: Authors have no competing interests to declare.
DATA AVAILABILITY STATEMENT: No new data were generated by this research. See text for references to accessible data resources.
Data Availability
No new data were generated by this research. See text for references to accessible data resources.
https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/
